Curated studies for research on COVID-19

31 Aug 2020

Curated COVID-19 data

NEBION continuously curates COVID-19 related gene expression studies and integrates them into GENEVESTIGATOR®. Using our unique tools, scientists can characterize this disease at the molecular level from multiple perspectives and compare results with thousands of other public datasets.

The following table describes high-quality human and mouse RNA-Seq and microarray studies that have been deeply curated and integrated into GENEVESTIGATOR® for research on COVID-19. Included in this collection are primarily studies investigating molecular changes associated with SARS-CoV-2 infections, as well as secondary studies investigating experimental COVID-19 treatments (repurposed) in the context of their original use.

To learn more about GENEVESTIGATOR® and how you can analyze and visualize this data, visit the GENEVESTIGATOR® website.

GENEVESTIGATOR® ID Repository ID (s) Study Title Number of Samples
HS-03448 GSE100496/ GSE100504/ GSE100509/ GSE65574/ GSE79172/ GSE79218/ GSE79458/ GSE81909/ GSE86528/ GSE86529/ GSE86530 (part of GSE65575) Modeling Host Responses to Understand Severe Human Virus Infections 542
HS-03495 GSE150392 RNA-Seq of Human iPSC-cardiomyocytes infected with SARS-CoV-2 6
HS-03479 GSE150316 Spectrum of Viral Load and Host Response Seen in Autopsies of SARS-CoV-2 Infected Lungs 32
HS-03524 GSE151161 Blocking of the CD80/86 axis as a therapeutic approach to prevent progression to more severe forms of COVID-19 76
HS-03482 GSE149273 RV infections in asthmatics increase ACE2 expression and stimulate cytokine pathways implicated in COVID19 90
HS-03493 GSE151803 Identification of Lead Drug Candidates for COVID-19 based on Drug Screening Using Human Pluripotent Stem Cell-Derived Cells/Organoids 16
HS-03502 GSE148729 Gene expression profiling of SARS-CoV-1 & 2 infected human cell lines at bulk and single-cell level (total RNA) 14
HS-03490 GSE148729 Gene expression profiling of SARS-CoV-1 & 2 infected human cell lines at bulk and single-cell level (poly A) 70
HS-03525 GSE153970 Primary Human Airway Epithelial Cultures infected with SARS-CoV-2 6
HS-03527 GSE154613 Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds 63
HS-03480 GSE150819 Generation of human bronchial organoids for SARS-CoV-2 research. 18
HS-03481 GSE149312 Bulk RNA sequencing of SARS-CoV and SARS-CoV-2 infected human intestinal organoids. 22
HS-00702 GSE17400 Dynamic Innate Immune Responses of Human Bronchial Epithelial Cells against SARS-CoV and DOHV infection. 27
HS-03427 GSE47963 (superseries of GSE47960, GSE47961, GSE47962) SARS-CoV, SARS-dORF6 and SARS-BatSRBD infection of HAE cultures. 438
HS-03426 GSE45042 Cell host-response to infection with novel human coronavirus EMC predict potential antivirals and important differences with SARS-coronavirus 32
HS-03424 GSE56677 Cytokine stimulation systems approach demonstrates differences in innate and pro-inflammatory host responses between genetically distinct MERS-CoV isolates. 32
HS-03423 GSE37827 SCL006, icSARS CoV Urbani or icSARS Bat SRBD (spike receptor binding domain from the wild type strain Urbani to allow for infection of human and non-human primate cells) infections of the 2B4 clonal derivative of Calu-3 cells - Time course 87
HS-03422 GSE33267 SCL005: icSARS CoV Urbani or icSARS deltaORF6 infections of the 2B4 clonal derivative of Calu-3 cells - Time course 99
HS-03420 GSE147507 Transcriptional response to SARS-CoV-2 infection 67
HS-03375 GSE148817 (part of GSE148818) Cell-intrinsic differences between human tracheal epithelial cells from children and adults 6
HS-03244 GSE78068 Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study 209
HS-02837 GSE25160 Combination of peripheral blood gene expression profiles and clinical parameters predicts response for tocilizumab (anti-IL6) treatment in rheumatoid arthritis 26
HS-02781 GSE46293 (Superserie of GSE46280, GSE46282, GSE46283, GSE46292) Expression data of multiple sclerosis patients receiving Interferon-beta therapy 24
HS-01798 GSE56192 (part of GSE56189) Transcriptomic analysis of the Novel Middle East Respiratory Syndrome Coronavirus (Human, MRC5 cells) 25
HS-01477 GSE17183 Hepatic gene expression before and during interferon and ribavirin combination therapy 98
HS-01237 GSE45867 Effects of tocilizumab versus methotrexate therapy on gene expression profiles in the early rheumatoid arthrtis synovium 40
HS-00214 GSE7123 Gene profiling of responders and non-responders to antiviral therapies peg interferon and ribavirin against hepatitis C 341
MM-01639 GSE148829 SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues 65
MM-01685 GSE150847 Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment 6
MM-01637 GSE59185, GSE52920 Host responses contributing to the attenuation of severe acute respiratory syndrome coronaviruses missing E protein domains / GSE52920 18
MM-01636 GSE131936 Relative timing of type I interferon response and virus replication determines disease outcome during MERS-CoV infection 16
MM-01635 GSE146074 LY6E blocks coronavirus fusion and confers immune control of viral disease 36
MM-01632 GSE49262, GSE49263 SM012 - SARS MA15 wild type, and SARS deltaORF6 mutant virus infections of C57BL6 mice - A time course 75
MM-00498 GSE21583 Effects of ACE2 on BMPR2 mutation-mediated defects in gene expression 8
MM-01448 GSE84709 Expression data of Brain CD11b+ cells from WT and DP1 knockout mice infected with rJ2.2 7
MM-01140 GSE36016 Transcriptomic analysis of host response to mouse-adapted SARS virus in wild type, STAT1 -/-, and IFNAR1 -/- mouse genetic backgrounds 36
MM-01109 GSE51386 SM004 - SARS infection of C57BL6, TIMP1 and Serpine1 knock-out mice 38

Table: These human and mouse RNA-Seq and Microarray studies in GENEVESTIGATOR® investigate gene expression changes associated with SARS-CoV-2 and changes associated with experimental treatments of COVID-19.